目的：探讨丙戊酸镁缓释片对双相情感障碍躁狂发作患者疗效及血清白介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、胱甘肽过氧化物酶(GSH-PX)、超氧化物歧化酶(SOD)水平的影响。方法：选取2017年10月至2019年12月我院收治的双相情感障碍躁狂发作患者98例。按随机数字表法分为两组,各49例；对照组行碳酸锂治疗,观察组在碳酸锂基础上加服丙戊酸镁缓释片治疗,均治疗8周。观察两组疗效,比较两组不同时间点血清IL-1β、TNF-α、GSH-PX、SOD水平以及贝克-拉范森躁狂量表(BRMS)评分；统计治疗过程不良反应,评估安全性。结果：观察组治疗8周总有效率为93.88%,高于对照组(73.47%),差异有统计学意义(χ²=7.470,P<0.05)。重复测量方差分析显示,两组血清IL-1β、TNF-α、GSH-PX、SOD水平以及BRMS评分的时点、组间、时点与组别的交互效应显著(P<0.01)；治疗4周、8周,两组IL-1β、TNF-α水平及BRMS评分均降低,GSH-PX、SOD水平均提高,且观察组IL-1β、TNF-α水平及BRMS评分低于对照组,GSH-PX、SOD高于对照组,差异有统计学意义(P<0.05)。治疗过程观察组发生不良反应合计7例(14.29%),对照组6例(12.24%),不良反应率的组间比较差异无统计学意义(χ²=0.089,P=0.766>0.05)。结论：丙戊酸镁缓释片可明显调节炎症与氧化应激水平,提高双相情感障碍躁狂发作患者的治疗效果；且不会增加不良反应,安全可靠。

Objective: To investigate the efficacy of magnesium valproate sustained-release tablets on patients with bipolar affective mania, serum interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and glutathione Of enzymes (GSH-PX) and superoxide dismutase (SOD) levels.Methods: A total of 98 patients with bipolar disorder and manic episodes treated in our hospital from October 2017 to December 2019 were selected. The random number table was divided into two groups, 49 cases each; the control group was treated with lithium carbonate, and the observation group was treated with magnesium valproate sustained-release tablets on the basis of lithium carbonate, both of which were treated for 8 weeks. Observe the efficacy of the two groups, compare the serum levels of IL-1β, TNF-α, GSH-PX, SOD and the Baker-Rafanson Mania Scale (BRMS) scores at different time points in the two groups; calculate the adverse reactions during the treatment process, and evaluate the safety .Results: The total effective rate for the 8-week treatment in the observation group was 93.88%, which was higher than that in the control group (73.47%). The difference was statistically significant (χ² = 7.470, P <0.05).Repeated measures analysis of variance showed that the levels of serum IL-1β, TNF-α, GSH-PX, SOD, and BRMS scores at time points, between groups, time points, and groups had significant interaction effects (P <0.01); treatment 4 At week 8 and week 8, the levels of IL-1β, TNF-α, and BRMS scores decreased, and the levels of GSH-PX, SOD increased, and the levels of IL-1β, TNF-α and BRMS in the observation group were lower than those in the control group, and GSH -PX and SOD were higher than the control group, the difference was statistically significant (P <0.05).A total of 7 adverse reactions occurred in the observation group during treatment (14.29%) and 6 in the control group (12.24%). There was no significant difference in adverse reaction rates between the groups (χ² = 0.089, P = 0.766> 0.05).Conclusion: Magnesium valproate sustained-release tablets can significantly regulate the levels of inflammation and oxidative stress, and improve the treatment effect of patients with bipolar affective disorder mania; it will not increase adverse reactions and is safe and reliable.